Author

Michael Kreines

Observed names: M. Kreines, M.D. Kreines, Michael D. Kreines

Observed institutions: Allogene Therapeutics (United States), Christ Hospital

OpenAlex ID: A5004122861

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

2016 · Miguel Regueiro, Brian G. Feagan, et al. · Gastroenterology · 339

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

2016 · Joseph A. Murray, Ciarán P. Kelly, et al. · Gastroenterology · 138

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection

2023 · Matthew D. Sims, Sahil Khanna, et al. · JAMA Network Open · 83

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

2022 · Yaara Zisman‐Ilani, Kimberly D. Thompson, et al. · Alimentary Pharmacology & Therapeutics · 17

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

2024 · Colleen S. Kraft, Matthew Sims, et al. · Infectious Diseases and Therapy · 9

S2391 Concomitant Treatment of Secondary Lymphocytic Hypophysitis and Crohn’s Disease With Adalimumab

2021 · Balaj Rai, Christopher Rosse, et al. · The American Journal of Gastroenterology · 2

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

2024 · Colleen S. Kraft, Matthew Sims, et al. · Infectious Diseases and Therapy

Disseminated Blastomycosis in a Previously Stable Crohn's Disease Patient on Infliximab Therapy

2023 · Michael Kreines, Sabrina Newstead, et al. · Infectious Diseases in Clinical Practice

Works count: 8

Citation count: 588

H-index: 5

I10-index: 4